Catalyst calendar
Data as of 2026-08-19 16:00 UTC · tracked universe polled every 15 minutes
Three kinds of date: a PDUFA date (the deadline the FDA sets itself to decide on a drug application), an AdCom (an FDA advisory-committee meeting that reviews it in public), and a readout window (when a trial's results are expected). Dates marked confirmed by the company come from an 8-K or press-release quote; our estimate is a rule-derived window off the trial's registered primary-completion date (see methodology) — never shown the same way. Today: 200 estimated readout windows and 0 disclosed PDUFA/AdCom dates.
Next 7 days
| Date | Ticker | Phase | Event |
|---|---|---|---|
| 2026-08-19 today | $BMRN | Phase 1 | Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants NCT06738017 |
| 2026-08-19 today | $AMGN | Phase 3 | A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With… NCT06104124 |
| 2026-08-19 today | $ITCI | Phase 1 | PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of… NCT06299410 |
| 2026-08-21 in 2d | $PFE | Phase 1 | A Study to Learn How Different Amounts of the Study Medicine Called PF-07999415… NCT06965465 |
| 2026-08-23 in 4d | $PFE | Phase 1 | A Study to Learn About the Study Medicine (Called PF-07220060 in Combination… NCT05262400 |
| 2026-08-24 in 5d | $REGN | Phase 2 | A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy… NCT06161441 |
| 2026-08-26 in 7d | $AMGN | Phase 1 | Effect of Maridebart Cafraglutide on the Heart's Electrical Activity NCT07229157 |
| 2026-08-30 in 2w | $PFE | Phase 3 | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in… NCT06152575 |
| 2026-08-31 in 2w | $PFE | Phase 3 | A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults… NCT07543380 |
| 2026-08-31 in 2w | $PFE | Phase 1 | A Study to Compare the Blood Levels of Two Dosage Formulations of the Study… NCT07594769 |
| 2026-08-31 in 2w | $BMY | Phase 1 | A Phase 1 Study of Navlimetostat Tablet Formulations NCT07544628 |
| 2026-09-01 in 2w | $INCY | Phase 3 | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed… NCT04824092 |
| 2026-09-01 in 2w | $PFE | Phase 1 | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given… NCT05548127 |
| 2026-09-02 in 2w | $PFE | Phase 1 | A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult… NCT06137742 |
| 2026-09-03 in 2w | $INCY | Phase 1 | A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic… NCT07588139 |
| 2026-09-03 in 2w | $AMGN | Phase 1 | Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available… NCT07545226 |
| 2026-09-03 in 2w | $PFE | Phase 1 | A Study to Learn How Different Forms of the Study Medicine Called PF-08049820… NCT07597928 |
| 2026-09-05 in 2w | $BMY | Phase 1 | A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors NCT06730750 |
| 2026-09-08 in 3w | $MRTX | Phase 1 | A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose… NCT07723118 |
| 2026-09-10 in 3w | $PFE | Phase 1 | A Study to Learn About How Food Affects the Uptake of Study Medicine… NCT07731100 |
| 2026-09-12 in 3w | $PFE | Phase 1 | A Study to Learn How the Study Medicine Called Etrasimod is Taken up Into Blood… NCT07153159 |
| 2026-09-15 in 4w | $PFE | Phase 1 | A Study of MET233 in Combination With MET097 in Individuals With Obesity or… NCT06924320 |
| 2026-09-17 in 4w | $VRTX | Phase 3 | An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type… NCT06832410 |
| 2026-09-23 in 5w | $PFE | Phase 2 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With… NCT04557449 |
| 2026-09-25 in 5w | $VIR | Phase 1 | Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and… NCT05484206 |